New Treatment Option: Biocon Launches Yesafili, an Interchangeable Biosimilar for Retinal Diseases in the U.S.

New Treatment Option: Biocon Launches Yesafili, an Interchangeable Biosimilar for Retinal Diseases in the U.S.

For individuals and families navigating the challenges of inherited retinal diseases (IRDs) and other serious eye conditions, news of new treatment options is always a beacon of hope. Biocon Limited has announced the commercial launch of Yesafili (aflibercept-jbvf) in the United States, an interchangeable biosimilar to Eylea (aflibercept) 2 mg. This development is significant for the IRD community as it aims to expand access to affordable treatments for various retinal diseases, potentially offering more choices for managing vision-threatening conditions.

Yesafili is a vascular endothelial growth factor (VEGF) inhibitor, a type of medicine that works by blocking a protein linked to abnormal blood vessel growth in the eye. This mechanism is crucial for treating conditions where leaky blood vessels or fluid buildup can lead to vision loss. The U.S. Food and Drug Administration (FDA) approved Yesafili in May 2024, granting it an interchangeable designation. This means that, where state laws permit, pharmacists may substitute Yesafili for the reference product, Eylea, without needing a new prescription from the prescribing physician.

Yesafili is indicated for the treatment of several serious eye conditions that can lead to vision impairment. These include neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), and diabetic retinopathy (DR). These conditions affect millions of Americans, with an estimated 19.8 million adults in the United States living with age-related macular degeneration alone.

The FDA approval was supported by comprehensive analytical, non-clinical, and clinical evidence, including data from the Phase 3 INSIGHT clinical study. This study compared Yesafili with Eylea 2 mg in patients with diabetic macular edema and demonstrated no clinically meaningful differences in efficacy, safety, pharmacokinetics, and immunogenicity between the two treatments. Biocon's CEO & Managing Director, Shreehas Tambe, stated that the launch is an important step in expanding the global availability of biosimilar aflibercept 2 mg for patients with eye conditions, further strengthening the company's presence in ophthalmology.

The introduction of an interchangeable biosimilar like Yesafili is expected to improve patient access to high-quality biologic therapies and contribute to healthcare cost savings through increased biosimilar adoption. This can be particularly impactful for patients requiring long-term treatment for chronic retinal diseases. The launch follows a settlement agreement with Regeneron, the patent owner of Eylea, which paved the way for Yesafili's entry into the U.S. market.

As the IRD community continues to advocate for accessible and affordable treatments, the availability of new biosimilar options like Yesafili represents a positive step forward. This launch underscores the ongoing efforts within the biopharmaceutical industry to bring more choices to patients facing vision loss due to retinal diseases.